华润博雅生物投资者关系活动记录表 证券代码：300294 证券简称：博雅生物 华润博雅生物制药集团股份有限公司投资者关系活动记录表 编号：20260323 | | □特定对象调研 分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 电话会议 | | | 其他 | | 参与单位名称 | 见附件 | | 及人员姓名 | | | 时间 | 2026 年 3 月 23 日(周一)上午 10:00-11:00 | | 地点 | 不适用 | | | 副总裁：李寿孙 | | 上市公司接待 | 副总裁：梁化成 | | 人员姓名 | 财务总监、董事会秘书：潘宇轩 | | | 本次互动交流的情况主要如下： | | | 一、基本情况介绍 | | | 公司财务总监、董事会秘书潘宇轩先生就 2025 年年度经营 | | | 情况作基本介绍： | | | 报告期内，公司实现营业收入 20.59 亿元，同比增长 3.24 | | 投资者关系活 | 亿元，增幅 18.69%，主要因为同期合并口径的增加。其中，母 | | 动主要 ...

Group 1: Company Overview and Strategy - The company aims to strengthen its position as the only blood product platform within the China Resources Health sector during the 14th Five-Year Plan, focusing on "doing strong, optimizing, and expanding" [3] - The strategy includes enhancing plasma collection, terminal control, R&D innovation, and exploring international markets [3][4] Group 2: Plasma Collection and Growth Projections - The total plasma collection for 2025 is projected to be approximately 662 tons, representing a year-on-year growth of about 5% [4] - The integration of Green Cross (China) is expected to yield a plasma collection growth rate exceeding 10%, with an absolute increase of over 10 tons [4] Group 3: Product Development and Regulatory Approvals - The company has received production approvals for 10% intravenous immunoglobulin and tetanus immunoglobulin, with clinical trials for 20% subcutaneous immunoglobulin progressing steadily [3][5] - High-concentration intravenous immunoglobulin (pH4) has been officially approved for sale as of May 2025 [5][6] Group 4: Market Dynamics and Pricing Strategy - Blood product prices are anticipated to face downward pressure due to market competition, with price adjustments expected in 2026 following the Guangdong alliance procurement [8] - The company plans to enhance terminal control and refine management of agents to improve market influence and brand recognition [8] Group 5: Expansion and Regulatory Challenges - The number of plasma collection stations has significantly increased during the 14th Five-Year Plan, but growth may slow during the 15th Five-Year Plan due to rising industry concentration [9] - The establishment of new plasma stations is subject to government approvals, which introduces uncertainty [9] Group 6: Business Focus and Divestitures - The company has decided to focus solely on blood product development, transferring 80% of the equity in Boya Xinhao, which will no longer be included in the consolidated financial statements [10][11]